John V Duncia

USPTO Granted Patents = 54 (Patent Applications = 4)

EPO Patents = 18 (Patent Applications = 18)

Average Co-Inventor Count = 5.7

ph-index = 10

Forward Citations = 310(Granted Patents)

Inventors with similar research interests:

Location History:

Hockessin, DE (US) (2001 - 2009)
Newtown, PA (US) (2005 - 2024)

Company Filing History:

30 out of 3,681

Bristol-myers Squibb Compnay

patents

21 out of 234

Bristol-myers Squibb Pharma Company

patents

1 out of 10

Bristol-myers Squibb Pharma Corporation

patents

4. 2 out of 832,680

Other

patents

Years Active: 2001-2025

Loading Chart...

54 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12473304 - Heterocyclic PAD4 inhibitors (2025-11-18),

2. 11981680 - Substituted thienopyrroles as PAD4 inhibitors (2024-05-14),

3. 11299494 - Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators (2022-04-12),

4. 10618903 - Heteroaryl substituted aminopyridine compounds (2020-04-14),

5. 10544133 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2020-01-28),

6. 10294256 - Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses (2019-05-21),

7. 10294229 - Heteroaryl substituted aminopyridine compounds (2019-05-21),

8. 10202390 - Heteroaryl substituted aminopyridine compounds (2019-02-12),

9. 10023562 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2018-07-17),

10. 9657009 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2017-05-23),

11. 9546153 - Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators (2017-01-17),

12. 9221819 - Spirocyclic compounds as modulators of chemokine receptor activity (2015-12-29),

13. 9169252 - Heteroaryl substituted nicotinamide compounds (2015-10-27),

14. 8877749 - Spirocyclic compounds as modulators of chemokine receptor activity (2014-11-04),

15. 8642622 - Piperidinyl compound as a modulator of chemokine receptor activity (2014-02-04),

Title: John V Duncia: A Trailblazer in Innovation

Introduction:

John V Duncia, a prolific inventor hailing from Newtown, PA (US), has left an indelible mark in the field of innovation with his remarkable contributions. His journey is a testament to creativity, perseverance, and unwavering ingenuity.

Latest Patents:

Among his impressive repertoire of 52 patents, some of his latest groundbreaking inventions include "Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators" and "Heteroaryl substituted aminopyridine compounds." These patents demonstrate his expertise in developing compounds essential for treating inflammatory and autoimmune diseases, as well as cancer.

Career Highlights:

During his illustrious career, John V Duncia has graced the corridors of prestigious companies such as Bristol-Myers Squibb Company and Bristol-Myers Squibb Pharma Company. His tenure at these esteemed organizations has been marked by innovation and excellence in the pharmaceutical industry.

Collaborations:

Throughout his career, John V Duncia has had the privilege of working with esteemed colleagues such as Joseph B Santella and Daniel S Gardner. Their collaborative efforts have led to the development of cutting-edge pharmaceutical solutions that have had a profound impact on the field.

Conclusion:

In conclusion, John V Duncia stands as a shining example of creativity, perseverance, and ingenuity in the world of innovation. His passion for pushing the limits of what is possible continues to inspire inventors and entrepreneurs worldwide. John V Duncia's legacy as an innovative inventor and a visionary in the pharmaceutical industry is truly remarkable.

This text is generated by artificial intelligence and may not be accurate.